Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

“…The overall effects of NSAIDs and coxibs on CV risk are difficult to ascertain, as on the one hand, most of them, but not all, have prothrombotic effects due cyclo-oxygenase 2 inhibition, and on the other hand, these agents improve mobility of patients with RA, which might counterbalance the prothrombotic effects 90 91. Moreover, a possible interaction between some NSAIDs and aspirin has been reported as some NSAIDs may impair aspirin’s antiplatelet function 92 93 94 95 96. Conclusive evidence is not yet available and therefore the potential atherothrombotic risk of any NSAID or COXIB must be taken into account when prescribing these drugs according to recommendations from the European Medicines Agency, especially in patients with documented CV disease or in the presence of CV risk factors.…”

Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis

“…The Corrona registry has been described in detail elsewhere [17]. Briefly, the Corrona registry comprises a prospective US observational cohort of patients with arthritis who are enrolled by participating rheumatologists [17, 18]. The Corrona registry was founded in 2001.…”

The CORRONA database

“…At the end of our third year of existence, we can now say with some confidence that CORRONA is at that point. Earlier observations from the database published in abstract form 1-9 have recently been followed by full-length reports 10 and several other data submissions to both the annual meeting of the European League Against Rheumatism (EULAR) [11][12][13][14][15] as well as the annual meeting of the American College of Rheumatology. [16][17][18][19][20][21][22][23][24][25][26][27] It is apparent that the data have now been enriched and have matured to the point of clinical relevance.…”